Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
about
Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugsIndividualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction.Evaluating platelet aggregation dynamics from laser speckle fluctuations.Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.Clinical impact of circulating miR-26a, miR-191, and miR-208b in plasma of patients with acute myocardial infarction.Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.Resistance to antiplatelet drugs: what progress has been made?Prasugrel hydrochloride for the treatment of acute coronary syndromes.Impact of tailored anti-P2Y12 therapies in acute coronary syndromes.Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors.Switching P2Y12-receptor inhibitors in patients with coronary artery disease.Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.Assessment of platelet function in patients receiving tirofiban early after primary coronary intervention.Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome.Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity.Platelet Function Testing-Guided Antiplatelet TherapyPersonalizing antiplatelet therapies: What have we learned from recent trials?Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity.A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity.Individualized intensified antiplatelet therapy based on platelet reactivity testing reduces the incidence of cardiovascular events in patients undergoing percutaneous coronary intervention.Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.Impact of Test Conditions on ADP-Induced Platelet Function Results With the Multiplate Assay: Is Further Standardization Required?Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet InhibitiDual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience.The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome.
P2860
Q26795403-A9792AF1-D76B-4843-BC7D-B39A93870251Q33804996-C27F588A-8222-408F-B992-D1C911D445E6Q33847328-9E621C45-9A1B-4C13-8FC5-C7A212EBAA02Q33901678-4C96CA3F-07B7-4ADE-B44F-E267F3211D91Q35630654-ADFAC586-0E9A-4C53-8DC5-A85DE2A8089BQ35694667-4B68E519-D0EB-41F4-8AFF-06684421D2D1Q37497555-5088A978-B252-4D57-986B-47D56B8C42F1Q38258270-C58F31B3-3B40-48BC-A633-0EEDEAC2C34AQ38336838-60291195-DF1B-4F80-A111-50D6095D266FQ38444425-FF61C680-AC81-49A0-8C48-3AD249F18338Q38532527-1EE0C949-8C93-4B2F-94F3-1E2A7DF5BB2AQ38568711-B7FBF41E-416B-45FD-99E1-EE3D272BDD7BQ38958862-8A009C30-B240-4DAF-B057-5D83E7739DFEQ39127444-8A34915B-7BC9-4024-879E-32287C401E54Q39159683-D2052AAE-BC1E-46AF-8703-7C991E884C13Q39187857-58966884-AAA9-482B-88CA-EB42E9C7F40CQ39341052-5F61E07A-CAFE-4FFC-B9F3-28FAE9F8F4CFQ39382840-CCFEDB39-81E4-40E7-A05A-76805BE486F5Q39949483-B858F12D-547E-4096-9346-6A3597B231ACQ44706040-C9AD1ED1-FA42-44AF-96A5-02D1FC129049Q47112558-F31802F1-E611-4316-BB8C-9ADC9C01D3CDQ47134483-3DB42BCF-9AB9-458F-92A3-F895F8A39B22Q48507719-1483EE2A-7320-47E2-ACA5-88566C0C6051Q50073758-F9E81FCD-E56A-4096-8A34-E78C1E27F317Q50662100-ACE96703-1DD7-4E39-BE1A-27549707B020Q50980833-5A768940-9D7C-497D-A004-65F1007141CAQ51063040-E975AFBC-98E7-4CD2-BF55-B56201B5CC8CQ53393756-5326786F-EFE7-4DFA-BF5C-2D4478B0B9C7
P2860
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Optimizing P2Y12 receptor inhi ...... rel and high-dose clopidogrel.
@ast
Optimizing P2Y12 receptor inhi ...... rel and high-dose clopidogrel.
@en
type
label
Optimizing P2Y12 receptor inhi ...... rel and high-dose clopidogrel.
@ast
Optimizing P2Y12 receptor inhi ...... rel and high-dose clopidogrel.
@en
prefLabel
Optimizing P2Y12 receptor inhi ...... rel and high-dose clopidogrel.
@ast
Optimizing P2Y12 receptor inhi ...... rel and high-dose clopidogrel.
@en
P2093
P1476
Optimizing P2Y12 receptor inhi ...... rel and high-dose clopidogrel.
@en
P2093
Adrienn Tornyos
András Komócsi
András Vorobcsuk
Attila Kónyi
Balázs Magyari
Dániel Aradi
Gábor Veress
Iván G Horváth
József Faluközy
Tünde Pintér
P304
P356
10.1016/J.JACC.2013.12.023
P407
P577
2014-01-30T00:00:00Z